文献速递眼底病与葡萄膜炎

白塞综合征葡萄膜炎患者的临床特征分析

[Clinical features of patients with Behcet's uveitis].
PubMed 文献 · Zhonghua Yan Ke Za Zhi · 2020-01-01

该回顾性系列病例研究纳入北京协和医院1998年1月至2015年11月诊治的132例(233只眼)白塞综合征葡萄膜炎患者,总结其临床表现、并发症、视力变化及药物治疗方案。结果显示该病多见于青壮年男性,常双眼受累且以全葡萄膜炎为主,眼部并发症常见、视力受损明显;糖皮质激素联合免疫抑制剂为多数患者的一线治疗,顽固性病例加用生物制剂可显著减少复发。

要点

  • 白塞综合征葡萄膜炎多见于21~40岁男性,双眼受累占76.5%,全葡萄膜炎占83.3%。
  • 眼部并发症见于80.7%的患眼,并发性白内障占58.8%,黄斑水肿占59.1%。
  • 97.0%患者用糖皮质激素联合免疫抑制剂;16例顽固性病例加用生物制剂后复发频次显著减少。

核心结论

  • 白塞综合征葡萄膜炎主要累及青壮年男性,表现为双眼全葡萄膜炎,眼部并发症常见且视力严重受损。
  • 糖皮质激素联合免疫抑制剂对多数患者有效,顽固性病例加用生物制剂可取得较好疗效。

研究设计与样本

  • 回顾性系列病例研究,收集1998年1月至2015年11月北京协和医院眼科葡萄膜炎专业组诊治的白塞综合征葡萄膜炎患者临床资料。
  • 共纳入132例(233只眼)患者,整理临床表现、并发症、最佳矫正视力(最小分辨角对数视力)及药物治疗方案。
  • 采用χ²检验及Wilcoxon符号秩检验进行统计分析。

主要发现

  • 男性104例(78.8%),女性28例(21.2%),性别分布差异有统计学意义(χ²=43.76,P<0.01)。
  • 发病年龄为(28.9±8.7)岁,主要集中在21~40岁(102例,77.3%)。
  • 眼外表现前5位为口腔溃疡(132例,100.0%)、皮肤病变(103例,78.0%)、外阴溃疡(90例,68.2%)、关节受累(44例,33.3%)及针刺反应阳性(39例,29.5%)。
  • 双眼受累101例(76.5%),全葡萄膜炎110例(83.3%)为最主要类型;188只眼(80.7%)出现并发症。
  • 病程第8年,20.9%(9/43)的患眼最佳矫正视力<0.3,39.5%(17/43)的患眼最佳矫正视力>1.0。

关键数值与推荐

  • 最常见的眼前节并发症为并发性白内障(58.8%,137/233)。
  • 最常见的眼后节并发症为黄斑水肿(59.1%,114/193)。
  • 97.0%(128/132)的患者接受糖皮质激素联合免疫抑制剂治疗。
  • 16例顽固性病例加用生物制剂(肿瘤坏死因子拮抗剂或干扰素α)后,复发频次由4.0(1.0,5.5)次/年降至0.5(0.0,1.5)次/年,差异有统计学意义(Z=-2.81,P=0.005)。

临床怎么用

  • 对青壮年男性双眼全葡萄膜炎患者应警惕白塞综合征,注意询问口腔、皮肤、外阴溃疡及关节受累等眼外表现。
  • 诊治中应关注并发性白内障和黄斑水肿等常见并发症,并定期评估视力变化。
  • 多数患者可采用糖皮质激素联合免疫抑制剂治疗,顽固性病例可考虑加用生物制剂以减少复发。

局限性

  • 本研究为单中心回顾性病例系列研究,未设对照组。
  • 生物制剂疗效分析仅基于16例顽固性病例,样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To characterize the clinical features of patients with Behcet's uveitis. Methods: Retrospective case series study. Medical records of patients who were diagnosed as Behcet's uveitis in Peking Union Medical College Hospital between January 1998 and November 2015 were retrospectively reviewed. Information about the clinical manifestation, complication, best corrected visual acuity (logarithm of the minimum angle of resolution) and medication was collected. The correlation of visual acuity and the disease course, as well as inflammation relapse times before and after biological agents applied was analyzed. Chi square test and Wilcoxon signed-rank test were applied for statistical analysis. Results: A total of 132 patients (233 eyes) with Behcet's uveitis were included, among which 104 (78.8%) were male and 28 (21.2%) were female, with statistically significant difference (χ(2)=43.76, P<0.01). The average age at the onset of uveitis was (28.9±8.7) years, with most patients at 21-40 years (102 cases, 77.3%). Oral aphthae (132 cases, 100.0%) were the most frequent extraocular manifestations, followed by dermatologic lesions (103 cases, 78.0%), genital ulcers (90 cases, 68.2%), arthritis (44 cases, 33.3%) and positive pathergy test (39 cases, 29.5%). Ocular involvement was bilateral in 76.5% (101 cases) of the patients, and panuveitis was the most common type (110 cases, 83.3%). Complications were seen in 80.7% (188/233) of the eyes, with cataract (58.8%, 137/233) and macular edema (59.1%, 114/193) being the most common anterior and posterior segment complications, respectively. At the eighth year of uveitis, best corrected visual acuity decreased to less than 0.3 in 20.9% (9/43) of the eyes, and more than 1.0 in 39.5% (17/43) of the eyes. A combination of glucocorticoids and immune modulators remained the first line therapy (97.0%, 128/132) for Behcet's uveitis. For 16 refractory cases, an addition of biological agents significantly reduced the inflammation relapse [0.5 (0.0, 1.5) times per year vs. 4.0 (1.0, 5.5) times per year, Z=-2.81, P=0.005]. Conclusions: Behcet's uveitis mainly affects working-age males and manifests as bilateral panuveitis. Complications are commonly seen in uveitic eyes. Patients' visual acuity is significantly impaired. A combination of glucocorticoids and immune modulators is effective for most patients, but for refractory cases, an addition of biological agents provides better effects. (Chin J Ophthalmol, 2020, 56: 217-223). 目的: 总结白塞综合征葡萄膜炎(BU)的临床特点。 方法: 回顾性系列病例研究。收集1998年1月至2015年11月就诊于北京协和医院眼科葡萄膜炎专业组的BU患者,整理临床资料。总结BU的临床表现、并发症、最佳矫正视力(最小分辨角对数视力)及药物治疗方案。分析不同病程视力变化情况及生物制剂治疗前后BU复发次数。应用χ(2)检验及Wilcoxon符号秩检验进行统计学分析。 结果: 共纳入132例(233只眼)BU患者,其中男性104例(78.8%),女性28例(21.2%),性别分布差异有统计学意义(χ(2)=43.76,P<0.01)。BU发病年龄为(28.9±8.7)岁,主要集中在21~40岁(102例,77.3%)。口腔溃疡(132例,100.0%)、皮肤病变(103例,78.0%)、外阴溃疡(90例,68.2%)、关节受累(44例,33.3%)及针刺反应阳性(39例,29.5%)为BU前5位眼外表现。患者常双眼受累(101例,76.5%),全葡萄膜炎(110例,83.3%)为最主要的葡萄膜炎类型。共188只眼(80.7%)出现并发症,最常见的眼前、后节并发症分别为并发性白内障(58.8%,137/233)及黄斑水肿(59.1%,114/193)。病程前8年,患者视力呈下降趋势;在病程第8年,20.9%(9/43)的患眼最佳矫正视力<0.3,39.5%(17/43)的患眼最佳矫正视力>1.0。97.0%(128/132)的患者接受糖皮质激素联合免疫抑制剂治疗。16例顽固性BU加用生物制剂(肿瘤坏死因子拮抗剂或干扰素α)后BU复发频次显著减少,由4.0(1.0,5.5)次/年降至0.5(0.0,1.5)次/年,差异有统计学意义(Z=-2.81,P=0.005)。 结论: BU在青壮年男性中多见,常累及双眼,主要表现为全葡萄膜炎。患者眼部并发症极为常见,视力严重受损。糖皮质激素联合免疫抑制剂在多数情况下可控制眼内炎性反应,但对于顽固性葡萄膜炎,生物制剂的应用取得较好疗效。(中华眼科杂志,2020,56:217-223).

来源:Zhonghua Yan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu XS, Gao F, Zhao C, et al. [Clinical features of patients with Behcet's uveitis]. Zhonghua Yan Ke Za Zhi. 2020. PMID: 32187951. doi:10.3760/cma.j.issn.0412-4081.2020.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。